Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

To investigate the efficacy of erlotinib versus docetaxel in previously treated patients with advanced non-small-cell lung cancer (NSCLC) in an epidermal growth factor receptor (EGFR) -unselected patient population. The primary end point was progression-free survival (PFS). Secondary end points incl...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2014-06, Vol.32 (18), p.1902-1908
Hauptverfasser:	KAWAGUCHI, Tomoya, ANDO, Masahiko, KAMIMURA, Mitsuhiro, SAKAMOTO, Kazuhiro, YOSHIMI, Michihiro, SOEJIMA, Yoshifumi, TOMIZAWA, Yoshio, ISA, Shun-Ichi, TAKADA, Minoru, SAKA, Hideo, KUBO, Akihito, ASAMI, Kazuhiro, OKANO, Yoshio, FUKUDA, Masaaki, NAKAGAWA, Hideyuki, IBATA, Hidenori, KOZUKI, Toshiyuki, ENDO, Takeo, TAMURA, Atsuhisa
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents - therapeutic use Biological and medical sciences Biomarkers, Tumor - genetics Carcinoma, Non-Small-Cell Lung - drug therapy Disease-Free Survival Erlotinib Hydrochloride Female Humans Kaplan-Meier Estimate Lung Neoplasms - drug therapy Male Medical sciences Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Mutation Odds Ratio Pneumology Proportional Hazards Models Quinazolines - therapeutic use Receptor, Epidermal Growth Factor - genetics Taxoids - therapeutic use Treatment Outcome Tumors Tumors of the respiratory system and mediastinum
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!